Back to results
US 2026/0083832 A1Published application
Vaccine Composition For Stimulation Of Broad Spectrum Memory B Cell Expansion
AssigneeNant Holdings IP, LLC
InventorPatrick Soon-Shiong
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeNant Holdings IP, LLC
InventorPatrick Soon-Shiong
Estimating the term…
Provided herein are vaccine compositions for use in the stimulation of broad-spectrum memory B cell expansion in a patient that has been exposed or is at risk of exposure to an infectious agent of unknown etiology. The composition comprises IL-15 or an IL-15 analog and at least two toll-like receptor (TLR) agonists, wherein the agonists are targeted to different members of the TLR family. Further contemplated herein are compositions and methods of stimulating germinal B cell expansion in a patient, the composition comprising IL-15 or an IL-15 analog and a nucleic acid, wherein the nucleic acid encodes at least one immunogenic peptide, and wherein the composition is administered either subcutaneously or directly into a lymph node.
A vaccine composition for use in the stimulation of broad-spectrum memory B cell expansion in a patient that has been exposed or is at risk of exposure to an infectious agent of unknown etiology, the composition comprising IL-15 or an IL-15 analog and at least two toll-like receptor (TLR) agonists, wherein the agonists are targeted to different members of the TLR family.
A method of stimulating the expansion of memory B cells in a patient, the method comprising administering to a patient a B-cell vaccine composition comprising IL-15 or an IL-15 analog and at least two toll-like receptor (TLR) agonists, wherein the agonists are targeted to different members of the TLR family, and wherein the patient has been exposed to, or is at risk of exposure to, an infectious agent of unknown etiology.
A kit for use in stimulating the expansion of memory B cells in a patient, the kit comprising an effective amount of a B-cell vaccine composition comprising IL-15 or an IL-15 analog, at least two toll-like receptor (TLR) agonists, and directions for the use thereof, wherein the agonists are targeted to different members of the TLR family, and wherein the patient has been exposed to, or is at risk of exposure to, an infectious agent of unknown etiology.
A vaccine composition for use in the stimulation of germinal B cell expansion in a patient, the composition comprising IL-15 or an IL-15 analog and a nucleic acid, wherein the nucleic acid encodes at least one immunogenic peptide, and wherein the composition is administered either subcutaneously or directly into a lymph node.
Dependencies are inferred from the claim text.